RxDoctor Payments DataLook up a doctor →

Gincy Samuel, MD

Neurology · Dallas, TXNPI 1821298399

Payments from drug & device makers

$2,402,533in general payments, 2019–2025

Across 1,646 payments — averaging $1459.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$1.7M
  • Neurology Practice Consortium GPO, LLC$468K
  • Hyperfine Operations, Inc.$53K
  • AbbVie$52K
  • Lilly USA, LLC$33K
  • Eli Lilly$29K
  • plus $28K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.559$1,738,423
Neurology Practice Consortium GPO, LLC7$468,226
Hyperfine Operations, Inc.3$53,457
AbbVie(2 entities)215$52,388
Lilly USA, LLC91$33,143
Eli Lilly3$28,765
Amgen(2 entities)50$11,989
Biogen23$2,259
Lundbeck LLC38$1,965
UCB, Inc.55$1,042
Genentech USA, Inc.52$972
Teva Pharmaceuticals USA, Inc.41$799
Novartis71$747
Argenx US, Inc.31$736
Sunovion Pharmaceuticals Inc.36$591
Merz Pharmaceuticals, LLC17$578
AstraZeneca22$457
Upsher-smith Laboratories LLC38$425
Acorda Therapeutics, Inc17$358
Grifols USA, LLC16$337
Vanda Pharmaceuticals Inc.8$322
Acadia Pharmaceuticals Inc13$316
SK Life Science, Inc.16$286
Pfizer21$285
Sanofi16$283
Amneal Pharmaceuticals LLC22$274
Neurocrine Biosciences, Inc.11$273
Tonix Medicines, Inc.17$231
Biohaven Pharmaceutical Holding Company Ltd.17$229
TG Therapeutics, Inc.10$226
Takeda Pharmaceuticals U.S.A., Inc.8$186
Avanir Pharmaceuticals, Inc.9$155
Merz North America, Inc.4$152
Johnson & Johnson(2 entities)8$151
CSL Behring6$144
Alnylam Pharmaceuticals Inc.6$115
Adamas Pharmaceuticals, Inc.5$106
Biohaven Pharmaceuticals, Inc.5$100
Cycle Pharmaceuticals Inc3$91
Avion Pharmaceuticals5$81
Ipsen Biopharmaceuticals, Inc3$61
Tanabe Pharma America, Inc.4$59
Impel Pharmaceuticals LLC4$56
Jazz Pharmaceuticals Inc.2$54
Kyowa Kirin, Inc.3$52
GE HealthCare3$46
Harmony Biosciences LLC3$45
Hospira, Inc.3$43
NS Pharma, Inc.2$43
Neurelis, Inc.2$39
Greenwich Biosciences, Inc.2$28
Banner Life Sciences, LLC2$28
Mallinckrodt Enterprises LLC1$28
Octapharma USA, Inc.1$28
Axsome Therapeutics, Inc.1$22
Impel Pharmaceuticals Inc.1$21
Aucta Pharmaceuticals, Inc.1$20
Boston Scientific1$19
Avadel CNS Pharmaceuticals, LLC1$18
Scilex Pharmaceuticals Inc.1$18

How this compares

$2,402,533 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$375,776
Medicare patients
268
Services billed
61,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →